Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group.

@article{BarMeir1998BudesonideVP,
  title={Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group.},
  author={Simon Bar-Meir and Yehuda Chowers and Alexandra Lavy and Dana Abramovitch and Ahud Sternberg and George Leichtmann and Ron Reshef and Shmuel Odes and Michal Moshkovitz and R. H. Bruck and Rami Abraham Eliakim and Eran Maoz and Ulrich Mittmann},
  journal={Gastroenterology},
  year={1998},
  volume={115 4},
  pages={835-40}
}
BACKGROUND & AIMS Budesonide (BUD) is a potent steroid that undergoes extensive first-pass metabolism. BUD incorporated in a pH-dependent formulation has been proposed as an alternative treatment for Crohn's disease (CD). The aim of this study was to compare the efficacy and safety of BUD and prednisone (PRED) in the treatment of active CD involving the terminal ileum and/or the colon. METHODS Patients with mild to moderately active CD were included in a randomized, double-blind, double-dummy… CONTINUE READING

From This Paper

Topics from this paper.
47 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 47 extracted citations

Similar Papers

Loading similar papers…